ro6870810
Small moleculeexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 16, 2013 (NCT01987362)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
BRCA1 inhibitor
- DNA repair protein RAD51 homolog 1INHIBITOR
RAD51 inhibitor
Bromodomain and extra-terminal motif (BET) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1CCN(CCCNC(=O)C[C@@H]2N=C(C3=C(SC(C)=C3C)N4C(C)=NN=C24)C5=CC=C(Cl)C=C5)CC1- Mol. weight
- 540.123 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSTA3QN7788D ↗
- ChEMBLCHEMBL4297423 ↗
Also known as
- ro6870810
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03292172 | Phase 1 | Nov 8, 2017 | Roche |
| NCT03255096 | Phase 1 | Aug 28, 2017 | Roche |
| NCT03068351 | Phase 1 | Jun 26, 2017 | Roche |
| NCT02308761 | Phase 1 | Nov 6, 2014 | Roche |
| NCT01987362 | Phase 1 | Oct 16, 2013 | Roche |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 5 | 5 | 1 | 2013 |
1 organizations
Page 1 / 1